Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Puma Biotechnology, Inc. before investing.

In this article, we go over a few key elements for understanding Puma Biotechnology, Inc.’s stock price such as:

• Puma Biotechnology, Inc.’s current stock price and volume
• Why Puma Biotechnology, Inc.’s stock price changed recently
• Upgrades and downgrades for PBYI from analysts
• PBYI’s stock price momentum as measured by its relative strength

About Puma Biotechnology, Inc. (PBYI)

Before we jump into Puma Biotechnology, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Want to learn more about Puma Biotechnology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Puma Biotechnology, Inc..

Puma Biotechnology, Inc.’s Stock Price as of Market Close

As of April 16, 2026, 3:32 PM, CST, Puma Biotechnology, Inc.’s stock price was $7.255.

Puma Biotechnology, Inc. is down 3.01% from its previous closing price of $7.480.

During the last market session, Puma Biotechnology, Inc.’s stock traded between $7.225 and $7.610. Currently, there are approximately 50.34 million shares outstanding for Puma Biotechnology, Inc..

Puma Biotechnology, Inc.’s price-earnings (P/E) ratio is currently at 12.3, which is low compared to the Biotechnology industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Puma Biotechnology, Inc. Stock Price History

Puma Biotechnology, Inc.’s (PBYI) price is currently up 13.54% so far this month.

During the month of April, Puma Biotechnology, Inc.’s stock price has reached a high of $7.900 and a low of $6.455.

Over the last year, Puma Biotechnology, Inc. has hit prices as high as $7.898 and as low as $2.750. Year to date, Puma Biotechnology, Inc.’s stock is up 21.93%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Puma Biotechnology, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 15, 2026, there were analysts who downgraded Puma Biotechnology, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Puma Biotechnology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Puma Biotechnology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Puma Biotechnology, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Puma Biotechnology, Inc. (PBYI) by visiting AAII Stock Evaluator.

Relative Price Strength of Puma Biotechnology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 15, 2026, Puma Biotechnology, Inc. has a weighted four-quarter relative price strength of 18.54%, which translates to a Momentum Score of 88 and is considered to be Very Strong.

Want to learn more about how Puma Biotechnology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Puma Biotechnology, Inc. Stock Price: Bottom Line

As of April 16, 2026, Puma Biotechnology, Inc.’s stock price is $7.255, which is down 3.01% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Puma Biotechnology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.